Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aggressive Lymphoma after CD19 CAR T-Cell Therapy.
Kobbe G, Brüggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, Libertini S, Menssen HD, Maier HJ, Ulrich P, Gao J, Bruch PM, Liebers N, Radujkovic A, Seifert M, Schniederjohann C, Paramasivam N, Fitzgerald D, Seidel M, Esposito I, Germing U, Cadeddu RP, Nachtkamp K, Jäger P, Ulrych T, Fischer JC, Rox JM, Giesel F, Koch R, Antoch G, Distler JHW, Meuth SG, Jacobsen M, Hübschmann D, Lu J, Iaccarino I, Haas S, Damm F, Dietrich S. Kobbe G, et al. Among authors: germing u. N Engl J Med. 2024 Oct 3;391(13):1217-1226. doi: 10.1056/NEJMoa2402730. N Engl J Med. 2024. PMID: 39589371
Author Correction: Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. Schneider RK, et al. Among authors: germing u. Nat Med. 2024 Nov;30(11):3382. doi: 10.1038/s41591-024-03350-7. Nat Med. 2024. PMID: 39443719 No abstract available.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG; International Consortium on Myelodysplastic Syndromes. Komrokji RS, et al. Among authors: germing u. Lancet Haematol. 2024 Nov;11(11):e862-e872. doi: 10.1016/S2352-3026(24)00251-5. Epub 2024 Oct 9. Lancet Haematol. 2024. PMID: 39393368 Review.
AML typical mutations (CEBPA, FLT3, and NPM1) identify a high-risk CMML independent of CPSS-Mol classification.
Castaño-Díez S, López-Guerra M, Zugasti I, Calvo X, Schulz FI, Avendaño A, Mora E, Falantes-González JF, Azaceta G, Ibañez M, Chen-Liang TH, Notario Mc Donnell C, Amer-Salas N, Palomo L, Pomares H, Vila J, Bernal Del Castillo T, Jiménez-Vicente C, Esteban D, Guijarro F, Álamo Moreno JR, Cortés-Bullich A, Torrecillas-Mayayo V, Triguero A, Mont-de Torres L, Carcelero E, Cardús A, Germing U, Betz B, Rozman M, Arenillas L, Zamora L, Díez-Campelo M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: germing u. Blood Adv. 2024 Oct 10:bloodadvances.2024013648. doi: 10.1182/bloodadvances.2024013648. Online ahead of print. Blood Adv. 2024. PMID: 39388660
Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.
Mazzeo P, Ganster C, Wiedenhöft J, Shirneshan K, Rittscher K, Brzuszkiewicz EB, Steinemann D, Schieck M, Müller-Thomas C, Treiber H, Braulke F, Germing U, Sockel K, Balaian E, Schanz J, Platzbecker U, Götze KS, Haase D. Mazzeo P, et al. Among authors: germing u. Hemasphere. 2024 Sep 23;8(9):e70014. doi: 10.1002/hem3.70014. eCollection 2024 Sep. Hemasphere. 2024. PMID: 39315323 Free PMC article.
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity.
Moreno-Arciniegas A, García A, Kelm M, D'Amore F, da Silva MG, Sánchez-González J, Sánchez PL, López-Fernández T, Córdoba R, Asteggiano R, Camus V, Smink J, Ferreira A, Kersten MJ, Bolaños N, Escalera N, Pacella E, Gómez-Talavera S, Quesada A, Rosselló X, Ibanez B; RESILIENCE Trial Investigators. Moreno-Arciniegas A, et al. Eur J Heart Fail. 2024 Oct;26(10):2213-2222. doi: 10.1002/ejhf.3395. Epub 2024 Aug 30. Eur J Heart Fail. 2024. PMID: 39212445
MDS patient registries - achievements and challenges.
Steinmetz T, Totzke U, Kasprzak A, Schmitz S, Gattermann N, Germing U. Steinmetz T, et al. Among authors: germing u. Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05925-3. Online ahead of print. Ann Hematol. 2024. PMID: 39174754 Review.
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe.
Diez-Campelo M, Yucel A, Goyal RK, Parikh RC, Esterberg E, Jimenez M, Sluga-O'Callaghan M, Miteva D, Xiao H, Germing U. Diez-Campelo M, et al. Among authors: germing u. Future Oncol. 2024;20(27):1993-2004. doi: 10.1080/14796694.2024.2379228. Epub 2024 Aug 14. Future Oncol. 2024. PMID: 39140298 Free PMC article.
Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study.
Crisà E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymäki M, Jädersten M, Komrokji R, Platzbecker U, Haase D, Hofmann WK, Al Ali NH, Barraco D, Bargay JJ, Bernal T, López Cadenas F, Calvisi A, Capodanno I, Cerrano M, Ciancia R, Crugnola M, Kündgen A, Finelli C, Fozza C, Frairia C, Freja E, Ganster C, Kubasch AS, Jimenez MJ, Latagliata R, Hernandez Mohedo F, Molero A, Vara Pampliega M, Perez CA, Pietrantuono G, Poloni A, Pomares H, Recasens V, Rüfer A, Signori A, Hellstrom-Lindberg E, Fenaux P, Sanz G, Santini V. Crisà E, et al. Among authors: germing u. Leukemia. 2024 Oct;38(10):2259-2265. doi: 10.1038/s41375-024-02360-1. Epub 2024 Aug 5. Leukemia. 2024. PMID: 39103678
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al Ali N, Xicoy B, López-Cadenas F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Diaz Varela N, Platzbecker U, Haase D, Díez-Campelo M, Della Porta M, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D. Montoro MJ, et al. Among authors: germing u. Blood. 2024 Oct 17;144(16):1722-1731. doi: 10.1182/blood.2024023840. Blood. 2024. PMID: 39074355
440 results